EP1105420A1 - Cyclic prosaposin-derived peptides and uses thereof - Google Patents

Cyclic prosaposin-derived peptides and uses thereof

Info

Publication number
EP1105420A1
EP1105420A1 EP99943903A EP99943903A EP1105420A1 EP 1105420 A1 EP1105420 A1 EP 1105420A1 EP 99943903 A EP99943903 A EP 99943903A EP 99943903 A EP99943903 A EP 99943903A EP 1105420 A1 EP1105420 A1 EP 1105420A1
Authority
EP
European Patent Office
Prior art keywords
amino acid
peptide
acid
hydrophobic amino
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99943903A
Other languages
German (de)
English (en)
French (fr)
Inventor
David E. Wright
John S. O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myelos Corp
Original Assignee
Myelos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelos Corp filed Critical Myelos Corp
Publication of EP1105420A1 publication Critical patent/EP1105420A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to neurotrophic and analgesic peptides More particularly, the invention relates to cyclic peptides derived from the active region of saposin C which have neurotrophic and analgesic effects
  • Neurotrophic factors are proteins or peptides capable of affecting the survival, target innervation and/or function of neuronal cell populations (Barde, Neuron 2 1525- 1534, 1989)
  • nerve growth factor acts as a trophic factor for forebrain cholinergic, peripheral and sensory neurons (Hefti et al , Neurobiol Aging 10 515-533, 1989) and can reverse naturally-occurring as well as physical traumatic injuries to peripheral nerves (Rich et al , J Neurocytol 16 261-268, 1987)
  • Brain- de ⁇ ved neurotrophic factor (BDNF) is a trophic factor for pe ⁇ pheral sensory neurons, dopaminergic neurons of the substantia nigra, central cholinergic neurons and retinal ganglia (Henderson et al , Restor Neurol Neurosci 5 15-28, 1993
  • Prosaposin is the precursor of a group of four small heat-stable glycoproteins which are required for hydrolysis of glycosphingolipids by lysosomal hydrolases (Kishimoto et al , J Lipid Res 33 1255-1267, 1992) Prosaposin is proteolytically processed in lysosomes, generating saposins A, B, C and D (O'Brien et al , FASEB J 5 301-308, 1991) O'Brien et al (Proc Natl Acad Sa USA 91 9593-9596, 1994),
  • U S Patent No 5,571,787 and published PCT Application No WO95/03821 disclose that prosaposin, saposin C stimulate neurite outgrowth and promote increased myelination
  • U S Patent Nos 5,571,787, 5,696,080, 5,714,459 and published PCT application No WO95/03821 disclose that a 22-mer peptide (CEFLVKEVTKLLDNNK
  • the active neu ⁇ togenic fragment was localized to a linear 12-mer sequence located within the amino terminus of saposin C (LIDNNKTEKEIL, SEQ LD NO: 3) (O'Brien et al, FASEB J. 9:681-685, 1994).
  • the present invention provides cyclic prosaposin peptidomimetics which have good resistance to proteolytic degradation and are capable of crossing the blood brain barrier.
  • One embodiment of the present invention is a cyclic neurotrophic and analgesic peptide having between about 1 1 and 25 amino acids, and including the sequence
  • Xi is a hydrophobic amino acid (alanine, leucine, isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine);
  • X 2 is a hydrophobic amino acid,
  • X 3 is aspartic acid, glutamic acid, lysine or arginine;
  • N is asparagine,
  • X 4 is any amino acid;
  • T is threonine;
  • X 5 is glutamic acid or aspartic acid;
  • X ⁇ is any amino acid, X is a hydrophobic amino acid; and
  • X 8 is a hydrophobic amino acid.
  • the peptide has the amino acid sequence shown in SEQ LD NO: 5 or 6.
  • the present invention also provides a composition
  • a composition comprising the peptide described above in a septum sealed vial, formulated with a controlled release material, in lyophilized form, in liposomal form, in a form suitable for topical administration or in unit dosage form.
  • Another embodiment of the present invention is a method for inducing myelination or inhibiting demyelination in a mammal, comprising administering to a mammal afflicted with demyelination a pharmaceutically effective demyelination inhibiting amount of a cyclic peptide having between about 11 and 25 amino acids, and including the sequence X]X 2 X 3 NNX4TX X6X7X , wherein Xi is a hydrophobic amino acid (leucine, isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine); X 2 is a hydrophobic amino acid, X 3 is aspartic acid, glutamic acid, lysine or arginine; N is asparagine, is any amino acid; T is threonine; X 5 is glutamic acid or aspartic acid; X 6 is any amino acid, X 7 is a hydrophobic amino acid;
  • the peptide is administered in a pharmaceutically acceptable carrier.
  • the peptide is enclosed in a lamellar structure.
  • the peptide has the sequence shown in SEQ LD NOS: 5 or 6.
  • the mammal is a human.
  • the present invention also provides a method for inhibiting neural degeneration or promoting neurite outgrowth in neural tissue, comprising: contacting neural tissue susceptible to such degeneration with an effective neural degeneration-inhibiting amount of a cyclic peptide having between about 11 and 25 amino acids, and including the sequence X]X 2 X 3 NNX TX 5 X6X 7 X 8 , wherein Xi is a hydrophobic amino acid (leucine, isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine); X 2 is a hydrophobic amino acid, X 3 is aspartic acid, glutamic acid, lysine or arginine; N is asparagine, X is any amino acid; T is threonine; X 5 is glutamic acid or aspartic acid; X ⁇ is any amino acid, X 7 is a hydrophobic amino acid; and X 8 is a hydrophobic amino acid.
  • Xi
  • the administration is intravenous, intramuscular, intradermal. subcutaneous, intracranial, intracerebrospinal or topical.
  • the peptide is administered in a pharmaceutically acceptable carrier.
  • the peptide is enclosed in a lamellar structure.
  • the mammal is a human.
  • Still another embodiment of the invention is a method for treating neuropathic pain in a mammal in need thereof, comprising the step of administering to a mammal suffering from neuropathic pain an amount of a cyclic peptide effective to inhibit neuronal degeneration, wherein said peptide peptide has between about 11 and 25 amino acids, and including the sequence X ⁇ X 2 X 3 NNX4TX 5 X6X 7 X , wherein Xi is a hydrophobic amino acid (leucine, isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine); X is a hydrophobic amino acid, X 3 is aspartic acid, glutamic acid, lysine or arginine; N is asparagine, X is any amino acid; T is threonine; X 5 is glutamic acid or aspartic acid; X 6 is any amino acid, X is a hydrophobic amino acid; and
  • the peptide has the amino acid sequence shown in SEQ LD NOS: 5 or 6.
  • the peptide is administered in a pharmaceutically acceptable carrier.
  • the peptide is enclosed in a lamellar structure.
  • the mammal is a human.
  • the present invention also provides a cyclic peptide having between about 1 1 and 25 amino acids, and including the sequence X ⁇ X 2 X 3 NNX 4 TX 5 X 6 X X 8 , wherein Xi is a hydrophobic amino acid (leucine, alanine isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine); X 2 is a hydrophobic amino acid, X 3 is aspartic acid, glutamic acid, lysine or arginine; N is asparagine, X is any amino acid; T is threonine; Xs is glutamic acid or aspartic acid; X 6 is any amino acid, X 7 is a hydrophobic amino acid; and X 8 is a hydrophobic amino acid, for use in inducing myelination or inhibiting demyelination in a mammal.
  • the peptide has the sequence shown in SEQ LD
  • Another embodiment of the invention is a cyclic peptide having between about 1 1 and 25 amino acids, and including the sequence X ⁇ X X 3 NNX 4 TX 5 X6X 7 X 8 , wherein Xi is a hydrophobic amino acid (leucine, alanine isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine); X 2 is a hydrophobic amino acid, X 3 is aspartic acid, glutamic acid, lysine or arginine; N is asparagine, X is any amino acid; T is threonine; X5 is glutamic acid or aspartic acid; X ⁇ is any amino acid, X 7 is a hydrophobic amino acid; and X 8 is a hydrophobic amino acid for use in inhibiting neural degeneration or promoting neurite outgrowth.
  • the peptide has the sequence shown in SEQ ID NO: a hydrophobic amino acid
  • the present invention also provides a cyclic peptide having between about 11 and 25 amino acids, and including the sequence X ⁇ X X NNX TX 5 X6X 7 X 8 , wherein Xi is a hydrophobic amino acid (leucine, alanine isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine); X 2 is a hydrophobic amino acid, X 3 is aspartic acid, glutamic acid, lysine or arginine; N is asparagine, X 4 is any amino acid; T is threonine; X5 is glutamic acid or aspartic acid; X ⁇ is any amino acid, X 7 is a hydrophobic amino acid; and X 8 is a hydrophobic amino acid for use in treatment of neuropathic pain.
  • Xi is a hydrophobic amino acid (leucine, alanine isoleucine, valine, tyrosine
  • the peptide has the sequence shown in SEQ LD NOS: 5 or 6 Detailed Description of the Preferred Embodiment
  • the present invention provides cyclic saposin C-derived peptides having between about 1 1 and 25 amino acids, and including the consensus sequence (SEQ LD NO: 4), wherein X, is a hydrophobic amino acid (alanine, leucine, isoleucine, valine, tyrosine, tryptophan, phenylalanine or methionine); X 2 is a hydrophobic amino acid, X 3 is aspartic acid, glutamic acid, lysine or arginine; N is asparagine, X4 is any amino acid; T is threonine; X5 is glutamic acid or aspartic acid; X ⁇ is any amino acid, X 7 is a hydrophobic amino acid; and X 8 is a hydrophobic amino acid.
  • X is a hydrophobic amino acid (alanine, leucine
  • the peptide has the sequence: cyclo-[LLDNNKTEKLY] (SEQ LD NO: 5) or cyclo-[LLDNNATEELL] (SEQ ID NO: 6). Due to their constrained structures, these cyclic prosaposin peptidomimetics are significantly more resistant to enzymatic degradation and are capable of crossing the blood brain barrier to a greater extent than corresponding linear peptides.
  • the cyclic peptides of the invention are equally as effective or more effective in stimulating neurite outgrowth than a known highly-active linear prosaposin peptidomimetic ("prosaptide") having the sequence TXLIDNNATEEILY, wherein X is D-alanine (SEQ ID NO: 7) (Example 1).
  • the cyclic peptides of the invention are more effective than prosaptide in preventing neural cell death in vitro (Example 2). These cyclic peptides lack free amino- and carboxy-terminal ends. Thus, they are more resistant to degradation in vivo by aminopeptidases and carboxypeptidases which degrade peptides from the amino-and carboxy-termini. Cyclic saposin C-derived peptides comprising the active 11-mer region (SEQ ID NO:
  • neurotrophic analogs thereof have utility in promoting functional recovery after toxic, traumatic, ischemic, degenerative and inherited lesions to the peripheral and central nervous system.
  • these peptides stimulate myelination and counteract the effects of demyelinating diseases.
  • These peptides stimulate the outgrowth of neurons, promote myelination, promote neuroprotection and prevent programmed cell death in neuronal tissues in mammals, preferably humans.
  • the peptides of the invention can also be used to treat various neuropathies including, but not limited to, motor, sensory, peripheral, taxol-induced and diabetic neuropathies.
  • a neuropathy is a functional disturbance or pathological change in the peripheral nervous system and is characterized clinically by sensory or motor neuron abnormalities.
  • the peptides are also useful as analgesics, particularly for the treatment of neuropathic pain in a mammal, preferably a human, which can develop days or months after a traumatic injury and is often long-lasting or chronic.
  • the second asparagine residue within the native prosaposin sequence (corresponding to second "N" in SEQ ID NO: 4 ) is known to be glycosylated with N-acetylglucosamine which may provide some resistance to proteolytic degradation.
  • One embodiment of the present invention is a method of facilitating neurite outgrowth or increased myelination in differentiated or undifferentiated neural cells by administering to the cells an effective, neurite outgrowth or myelin-facilitating amount of a saposin C-derived peptide encompassing the active cyclic 1 1-mer region shown in SEQ ID NO:4.
  • Saposin C-derived cyclic peptide analogs of the invention can differ from saposin C sequences or SEQ ID NOS: 4-6, for example, by replacement of one or more lysine and/or arginine residues; replacement of one or more tyrosine and/or phenylalanine residues, deletion of one or more phenylalanine residues and/or conservative replacement of one or more amino acids within the peptide.
  • the replacement or deletion of lysine/arginine and tyrosine/phenylalanine residues will reduce the susceptibility of peptide degradation by trypsin and chymotrypsin, respectively.
  • the cyclic neurotrophic and myelinotrophic peptide sequences of the invention preferably have up to about 50 amino acids; more preferably, up to about 30 amino acids; and most preferably, between about 11 and 25 amino acids and include therein the sequence shown in SEQ ID NO: 4.
  • peptide sequences contemplated for use in the present invention include minor insertions, deletions and substitutions.
  • conservative amino acid replacements are contemplated. Such replacements are, for example, those that take place within a family of amino acids that are related in the chemical nature of their side chains.
  • the families of amino acids include the basic charged amino acids (lysine, arginine, histidine); the acidic charged amino acids (aspartic acid, glutamic acid); the non-polar amino acids (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan); the uncharged polar amino acids (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine); and the aromatic amino acids (phenylalanine, tryptophan and tyrosine).
  • the basic charged amino acids lysine, arginine, histidine
  • the acidic charged amino acids aspartic acid, glutamic acid
  • non-polar amino acids alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • the uncharged polar amino acids glycine, asparagine, glutamine,
  • conservative amino acid replacements consisting of an isolated replacement of a leucine with an isoleucine or valine, or an aspartic acid with a glutamic acid, or a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid will not significantly affect the properties of the peptide.
  • the cyclic saposin C-derived sequences including SEQ LD NO: 4 can be modified to attain various objectives such as increased activity and stability.
  • Other amino acids can be present outside this consensus sequence including native saposin C sequence, conservative substitutions of these native sequences, or unrelated peptide sequences to achieve objectives such as increased binding, hydrophobicity, hydrophilicity and the like. Sequences outside the active neurotrophic region are not typically required for activity. Thus, in most instances, the subject peptide will be active regardless of the identity of these sequences. Again, any such peptide can be screened for such activity using the protocols described herein.
  • any such cyclic peptide to stimulate neurite outgrowth, prevent neural cell death, promote myelination, inhibit demyelination, alleviate neuropathic pain and treat sensory neuropathy can easily be dete ⁇ nined by one of ordinary skill in the art using the procedures described in Examples 1-9. Methods for assaying the abilities of these peptides to promote myelination and to inhibit demyelination are set forth in Examples 3 and 4 hereinbelow.
  • a typical minimum amount of the peptides of the invention for the neurotrophic activity in cell growth medium is usually at least about 5 ng/ml. This amount or more of the cyclic synthetic peptides of the invention for in vitro use is contemplated.
  • concentrations in the range of 0.1 ⁇ g/ml to about 10 ⁇ g/ml of these peptides will be used.
  • Effective amounts for any particular tissue can be determined in accordance with Example 1.
  • the neural cells can be treated in vitro or ex vivo by directly administering the peptides of the invention to the cells. This can be done, for example, by culturing the cells in growth medium suitable for the particular cell type, followed by addition of the peptide to the medium.
  • the composition can be administered by one of several techniques. Most preferably, the composition is injected directly into the blood or tissue in sufficient quantity to give the desired local concentration of peptide.
  • the peptides of the invention may also be esterified with fatty acids to form peptide fatty acid esters using conventional acid-catalyzed esterification.
  • the last amino acid added in the synthetic procedure is itself a commercially available esterified amino acid which obviates the need for the esterification reaction.
  • Fatty acids contemplated for use in formation of peptide esters include lauric, myristic, palmitic, stearic, oleic and linoleic.
  • the subject peptides may also be acetylated by inclusion of commercially available acetylated lysine, arginine or asparagine residues during the synthetic procedure. These modified peptides retain the activity of the parent compound. Such modifications will facilitate the ability of the peptide to cross the blood brain barrier due to increased hydrophobicity.
  • direct intracranial injection or injection into the cerebrospinal fluid may also be used in sufficient quantities to give the desired local concentration of neurotrophin.
  • a pharmaceutically acceptable injectable carrier is used.
  • Such carriers include, for example, phosphate buffered saline and Ringer's solution.
  • the composition can be administered to peripheral neural tissue by direct local injection or by systemic administration.
  • Various conventional modes of administration are contemplated, including intravenous, intracerebrospinal, intramuscular, intradermal, subcutaneous, intracranial, intranasal, epidural, topical and oral.
  • administration by direct intramuscular or intravenous injection is prefe ⁇ ed.
  • the peptide compositions of the invention can be packaged and administered in unit dosage form, such as an injectable composition or local preparation in a dosage amount equivalent to the daily dosage administered to a patient or as a controlled release composition.
  • a septum sealed vial containing a daily dose of the active ingredient in either PBS or in lyophilized form is an example of a unit dosage.
  • Appropriate daily systemic dosages of the peptides of the invention based on the body weight of the vertebrate for treatment of neural diseases, demyelination or as an analgesic in general or for treatment of neuropathic pain are in the range of from about 0.01 to about 10,000 ⁇ g/kg. More preferably, daily systemic dosages are between about 0.1 and 1,000 ⁇ g/kg.
  • daily systemic dosages are between about 10 and 100 ⁇ g/kg.
  • dosages can be between about 0.7 and 700,000 ⁇ g daily; more preferably between about 7 and 70,000 ⁇ g daily; and most preferably between about 700 and 7,000 ⁇ g/kg.
  • Daily dosages of locally administered material will be about an order of magnitude less. Oral administration is also contemplated.
  • the neurotrophic peptides are administered locally to neural cells in vivo by implantation thereof.
  • polylactic acid, polygalactic acid, regenerated collagen, multilamellar liposomes and many other conventional depot formulations is expressly contemplated in the present invention.
  • Infusion pumps, matrix entrapment systems and combination with transdermal delivery devices are also contemplated.
  • the peptides may also be encapsulated within a polyethylene glycol conformal coating as described in U.S. Patent No. 5,529,914 prior to implantation.
  • the neurotrophic peptides of the invention may also be enclosed in micelles or liposomes.
  • Liposome encapsulation technology is well known. Liposomes may be targeted to specific tissue, such as neural tissue, through the use of receptors, ligands or antibodies capable of binding the targeted tissue. The preparation of these formulations is well known in the art (Radin et al., Meth. Enzymol, 98:613-618, 1983).
  • neurotrophic factors can be therapeutically useful in the treatment of neurodegenerative diseases associated with the degeneration of neural populations or specific areas of the brain.
  • the principal cause of Parkinson's disease is the degeneration of dopaminergic neurons of the substantia nigra. Since antibodies against prosaposin immunohistochemically stain the dopaminergic neurons of the substantia nigra in human brain sections, the neurotrophic peptides of the invention may be therapeutically useful in the treatment of Parkinson's disease.
  • Retinal neuropathy an ocular neurodegenerative disorder leading to loss of vision in the elderly, is also treatable using the peptides of the invention. It has long been believed that in order to reach neuronal populations in the brain, neurotrophic factors would have to be administered intracerebrally since these proteins do not cross the blood brain barrier.
  • U.S. Patent No.5, 571, 787 discloses that an iodinated neurotrophic 18-mer fragment derived from saposin C crosses the blood brain barrier. Peptides of the present invention having up to about 22 amino acids will also cross this barrier and can thus be administered intravenously, with greater transport occurring for shorter peptides.
  • Other neuronal populations, such as motor neurons can also be treated by intravenous injection, although direct injection into the cerebrospinal fluid is also envisioned as an alternate route.
  • Cells may be treated to facilitate myelin formation or to prevent demyelination in the manner described above in vivo, ex vivo or in vitro.
  • Diseases resulting in demyelination of nerve fibers including MS, acute disseminated leukoencephalitis, progressive multifocal leukoencephalitis, metachromatic leukodystrophy and adrenal leukodystrophy can be slowed or halted by administration of the neurotrophic peptides of the invention to the cells affected by the disease. Reversal of demyelination diseases or other neural damage is also contemplated.
  • the compositions of the present invention can be used in vitro as research tools for studying the effects of neurotrophic factors and myelin facilitating materials. However, more practically, they have an immediate use as laboratory reagents and components of cell growth media for facilitating growth and maintaining neural cells in vitro.
  • the peptides of the invention are synthesized on a solid support using established methods and Fmoc chemistry using an automated solid-phase protocol well known in the art
  • Example 1 is illustrative and are not intended to limit the scope of the present invention.
  • NS20Y neuroblastoma cells were grown in DMEM containing 10% fetal calf serum (FCS). Cells were removed with trypsin and plated in 30 mm petri dishes onto glass coverslips. After 20-24 hours, the medium was replaced with 2 ml DMEM containing 0.5% FCS plus various concentrations of the peptide A, peptide B or TX14(A). Cells were cultured for an additional 24 hours, washed with PBS and fixed with Bouin's solution (saturated aqueous picric acid/formalin/acetic acid 15:5:1) for 30 minutes. Fixative was removed with PBS and neurite outgrowth was scored under a phase contrast microscope. Cells exhibiting one or more clearly defined neurites equal to or longer than one cell diameter were scored as positive. At least 200 cells were scored in different portions of each dish to determine the percentage of neurite bearing cells and assays were performed in duplicate.
  • FCS fetal calf serum
  • T [ 2 (ED 50 ) which is the concentration of peptide resulting in 50% increased neurite outgrowth, was 1.0 ng/ml for TX14(A) and for peptide B.
  • the T 1 2 for peptide A was 0.6 ng/ml.
  • peptide B was as effective as TX14(A), while peptide A was more effective than TX14(A). This indicates that the cyclized peptides of the present invention have excellent activity in comparison to an established standard "prosaptide".
  • Example 2 Prevention of cell death in vitro NS20Y cells were plated as described in Example 1 and grown on glass coverslips in 0.5%) fetal bovine serum for 2 days in the presence or absence of TX14(A), peptide A or peptide B Media was removed and 0.2% trypan blue in PBS was added to each well. Blue- staining dead cells were scored as a percentage of the total on an inverted microscope, counting 400 cells in four areas of each well. The average error of duplicates was 5%. TX14(A), peptide A and peptide B reduced the number of trypan blue-positive (dead) cells. The Tin (ED 50 ) for prevention of neural cell death for TX 14(A) was 1.0 ng/ml.
  • Peptides A and B were more potent, with T m values of 0.6 ng/ml and 0.8 ng/ml, respectively. This indicates that the cyclic peptides have exceptional activity in rescuing neural cells from programmed cell death in comparison to a standard linear "prosaptide".
  • Example 3 Ex vivo myelination assay Newborn mouse cerebellar explants are prepared according to Satomi (Zool. Set, 9:127-137, 1992). Neurite outgrowth and myelination are observed over 22 days in culture, during the period when the newborn mouse cerebellum normally undergoes neuronal differentiation and myelination begins. A cyclic saposin C-derived peptide having between 11 and 25 amino acids and containing the sequence shown in SEQ ED NO: 4 (10 ⁇ g/ml) is added on the second day after preparation of the explants (three control and three treated explants), and outgrowth of neurites and myelination is assessed under a bright field microscope with a video camera.
  • peptide-treated cultures contain many cells with long projections at the periphery of the explant which are less prominent in untreated control cultures.
  • Peptide-treated cultures contain significantly more myelinated axons in the subcortical white matter at 22 days compared to control explants.
  • the peptides of the invention induce increased myelination in differentiating cerebellum ex vivo.
  • the prevention of Schwann cell death is correlated with prevention of demyelination.
  • Schwann cells contain an extensive myelin sheath.
  • the addition of. a cyclic saposin C-derived peptide having between 11 and 25 amino acids and containing the sequence shown in SEQ LD NO: 4 to Schwann cells in culture reduces Schwann cell death in a dose-dependent manner and stimulates the incorporation of sulfatides, myelin-specific lipids, into Schwann cells. This indicates that the cyclic peptides of the invention can prevent demyelination due to Schwann cell death.
  • peptides in treating traumatic ischemic CNS lesions Humans with traumatic lesions to the spinal cord receive intracerebrospinal or direct injection of about 100 ⁇ g/ml of. a cyclic saposin C-derived peptide having between 11 and 25 amino acids and containing the sequence shown in SEQ LD NO: 4 in a sterile saline solution or in depot form to enable slow, continuous release of the peptide at the lesion site.
  • Improvement is assessed by gain of motor nerve function (i.e. increased limb movement). Treatments continue until no further improvement occurs.
  • Example 6 Use of peptides in treating demyelination disorders Patients diagnosed with early stage MS are given a cyclic saposin C-derived peptide having between 11 and 25 amino acids, and containing the sequence shown in SEQ LD NO: 4, by direct intravenous injection into the cerebrospinal fluid using the same dose range as in Example 3. Dosages are repeated daily every 2-5 days, or weekly and improvement in muscle strength, musculoskeletal coordination and myelination (as dete ⁇ nined by MRI) is observed.
  • Example 7 Alleviation of neuropathic pain in Chung model rats This example describes the effects of bolus intrathecal injection of a cyclic saposin C- derived peptide having between 11 and 25 amino acids and containing the sequence shown in SEQ LD NO: 4 in the Chung experimental model of peripheral neuropathic pain.
  • Each peptide is chemically synthesized, purified, dissolved in sterile PBS and buffered to neutral pH.
  • the surgical procedure previously described by Kim et al. (Pain, 50:355, 1992) is performed on male rats to induce an allodynic state.
  • a spinal catheter is introduced two weeks after surgery, Five days later, the peptides are administered at 0.007, 0.07 and 0.7 ⁇ g/rat.
  • Pressure thresholds are then determined using calibrated von Frey hairs. The longer the time taken for an animal to withdraw the paw in response to applied pressure, the less severe the neuropathic pain. The peptides significantly increase the threshold pressure, indicating a significant alleviation of neuropathic pain.
  • Example 8 Treatment of sensory neuropathy Mice are administered taxol in order to induce sensory neuropathy.
  • Taxol-treated mice are administered 50 ⁇ g kg, 100 ⁇ g/kg or 250 ⁇ g/kg of a cyclic saposin C-derived peptide having between 11 and 25 amino acids and containing the sequence shown in SEQ D NO: 4.
  • the loss of thermal sensation is measured using a Hargreaves sensory testing apparatus as an indicator or sensory neuropathy.
  • Each of the three doses of peptide is effective in preventing or retarding loss of thermal sensation in taxol-treated mice.
  • the synthetic saposin C-derived peptides of the invention effectively inhibit sensory neuropathy.
  • Rats are made diabetic by a single intraperitoneal injection of streptozotocin (50 mg/kg body weight, freshly dissolved in 0.9% sterile saline) to ablate pancreatic ⁇ cells and induce insulin deficiency as described by Calcutt et al. (Pain, 68:293-299, 1996). Two days later, diabetes is confirmed in streptozotocin-injected rats by measuring blood glucose levels. Streptozotocin-injected animals with a blood glucose concentration below 15 mmol/1 were excluded from subsequent studies, according to the commonly accepted definition of non- fasting hyperglycemia in studies of diabetes in rats.
  • Both diabetic and control rats are studied at 8 weeks by analyzing the behavioral response to the noxious chemical formalin as an indicator of allodynia (Calcutt et al., supra. 1996). Briefly, rats receive a subcutaneous injection of freshly-prepared formalin (50 ⁇ l of 0.5%) solution in sterile saline) into the dorsal surface of the right hind paw. This concentration of formalin induces sub-maximal behavioral responses in control rats and allows detection of hyperalgesia in diabetic rats during phases Q and 2 (Calcutt et al., Ewr. J Pharmacol, 285:189-197, 1995). Animals are transferred to an observation chamber constructed to allow continuous visualization of the paws.
  • Phase 1 is defined as the initial measurement of flinching (1-2 and 5-6 minutes post injection); the Q (quiescent) phase as the measurements made at 10-11, 15-16 and 20-21 minutes; and Phase 2 as all subsequent measurements post-injection, as previously defined for studies of diabetic rats (see, for example, Malmberg et al., Neurosci. Lett, 161:45-48, 1993). Comparisons of activity during each phase are made by surnming the flinches at measurement points within the phase, diabetic rats five an abnormal flinch response.
  • Diabetic rats are divided in two groups of four animals each which are administered saline or a cyclic saposin C-derived peptide having between 11 and 25 amino acids and containing the sequence shown in S ⁇ Q LD NO: 4, respectively.
  • Two hours before treatment with 0.5% formalin the diabetic rats are treated with saline or 200 ⁇ g/kg peptide using intraperitoneal administration.
  • Administration of peptide completely prevents the abnormal flinch response in Phase 1 and ameliorates the response in Phase 2 by 70%.
  • parenteral administration of peptide alleviates the pain from formalin injection and improves motor neuron function in a rat model of painful diabetic neuropathy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP99943903A 1998-08-28 1999-08-20 Cyclic prosaposin-derived peptides and uses thereof Withdrawn EP1105420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9835998P 1998-08-28 1998-08-28
US98359P 1998-08-28
PCT/US1999/019378 WO2000012553A1 (en) 1998-08-28 1999-08-20 Cyclic prosaposin-derived peptides and uses thereof

Publications (1)

Publication Number Publication Date
EP1105420A1 true EP1105420A1 (en) 2001-06-13

Family

ID=22268937

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99943903A Withdrawn EP1105420A1 (en) 1998-08-28 1999-08-20 Cyclic prosaposin-derived peptides and uses thereof

Country Status (13)

Country Link
EP (1) EP1105420A1 (enExample)
JP (2) JP4528443B2 (enExample)
KR (1) KR20010079695A (enExample)
CN (1) CN1324367A (enExample)
AU (1) AU751034B2 (enExample)
BR (1) BR9913490A (enExample)
CA (1) CA2341810A1 (enExample)
CZ (1) CZ2001655A3 (enExample)
HU (1) HUP0103265A3 (enExample)
IL (1) IL141586A0 (enExample)
PL (1) PL204359B1 (enExample)
WO (1) WO2000012553A1 (enExample)
ZA (1) ZA200102489B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
AU751034B2 (en) * 1998-08-28 2002-08-08 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
JP5437790B2 (ja) 2006-04-28 2014-03-12 チルドレンズ ホスピタル メディカル センター 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物
BRPI0717475A2 (pt) * 2006-10-20 2014-03-11 Childrens Hosp Medical Center Vesículas unilamelares de fosfolipídio elipsoidal de formação espontânea
CN103275187B (zh) * 2013-06-14 2014-10-29 四川合泰新光生物科技有限公司 一种镇痛肽fi及其基因和应用
BR112017022021B1 (pt) 2015-04-23 2021-07-06 The Procter & Gamble Company Composição para tratamento dos cabelos
EP3423031B1 (en) 2016-03-03 2021-09-08 The Procter & Gamble Company Aerosol antidandruff composition
CN109789076A (zh) 2016-10-21 2019-05-21 宝洁公司 具有低粘度和粘度降低剂的稳定致密洗发剂产品
CN109843258A (zh) 2016-10-21 2019-06-04 宝洁公司 表示毛发调理有益效果的浓缩型洗发剂泡沫剂型
US11141361B2 (en) 2016-10-21 2021-10-12 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair volume benefits
US10888505B2 (en) 2016-10-21 2021-01-12 The Procter And Gamble Company Dosage of foam for delivering consumer desired dosage volume, surfactant amount, and scalp health agent amount in an optimal formulation space
EP3528895A1 (en) 2016-10-21 2019-08-28 The Procter & Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
US20180110688A1 (en) 2016-10-21 2018-04-26 The Procter & Gamble Company Concentrated Shampoo Dosage of Foam for Providing Hair Care Benefits
US10842720B2 (en) 2016-10-21 2020-11-24 The Procter And Gamble Company Dosage of foam comprising an anionic/zwitterionic surfactant mixture
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
EP4427727A3 (en) 2017-10-10 2024-12-18 The Procter & Gamble Company Compact shampoo composition containing sulfate-free surfactants
JP6952906B2 (ja) 2017-10-10 2021-10-27 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 泡形態のパーソナルケア組成物で毛髪又は皮膚を処理する方法
EP3694481B1 (en) 2017-10-10 2024-06-05 The Procter & Gamble Company Compact shampoo composition with amino acid based anionic surfactants and cationic polymers
WO2019074992A1 (en) 2017-10-10 2019-04-18 The Procter & Gamble Company CLEANING ORGANIC HYGIENE COMPOSITION WITHOUT SULFATES WITH LOW INORGANIC SALT CONTENT
EP3727323A1 (en) 2017-12-20 2020-10-28 The Procter & Gamble Company Clear shampoo composition containing silicone polymers
MX2020014144A (es) 2018-06-29 2021-03-25 Procter & Gamble Composicion anticaspa en aerosol con bajo contenido de surfactante.
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents
JP7410298B2 (ja) 2019-12-06 2024-01-09 ザ プロクター アンド ギャンブル カンパニー 頭皮活性物質の付着を強化する硫酸塩を含まない組成物
JP7481470B2 (ja) 2020-02-27 2024-05-10 ザ プロクター アンド ギャンブル カンパニー 有効性及び美観が強化された硫黄含有フケ防止組成物
JP7678101B2 (ja) 2020-11-23 2025-05-15 ザ プロクター アンド ギャンブル カンパニー 硫酸化界面活性剤を含まないパーソナルケア組成物
JP7768985B2 (ja) 2020-12-04 2025-11-12 ザ プロクター アンド ギャンブル カンパニー 悪臭低減物質を含むヘアケア組成物
US12409125B2 (en) 2021-05-14 2025-09-09 The Procter & Gamble Company Shampoo compositions containing a sulfate-free surfactant system and sclerotium gum thickener
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
WO2023108097A1 (en) 2021-12-09 2023-06-15 The Procter & Gamble Company Sulfate free personal cleansing composition comprising effective preservation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639584A1 (en) * 1993-06-22 1995-02-22 Interpharm Laboratories Ltd. Preparation and screening of highly diverse peptide libraries for binding activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
AU751034B2 (en) * 1998-08-28 2002-08-08 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639584A1 (en) * 1993-06-22 1995-02-22 Interpharm Laboratories Ltd. Preparation and screening of highly diverse peptide libraries for binding activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGLETHON R. D.: "Bioavailability and transport of peptide drugs into the brain", PEPTIDES, vol. 18, no. 9, 1997, pages 1431 - 1439 *
See also references of WO0012553A1 *

Also Published As

Publication number Publication date
JP2010150272A (ja) 2010-07-08
ZA200102489B (en) 2002-06-04
HUP0103265A2 (hu) 2002-02-28
JP2002523518A (ja) 2002-07-30
HUP0103265A3 (en) 2002-09-30
KR20010079695A (ko) 2001-08-22
BR9913490A (pt) 2001-09-25
CN1324367A (zh) 2001-11-28
PL204359B1 (pl) 2010-01-29
PL346346A1 (en) 2002-02-11
AU751034B2 (en) 2002-08-08
WO2000012553A1 (en) 2000-03-09
CA2341810A1 (en) 2000-03-09
JP4528443B2 (ja) 2010-08-18
CZ2001655A3 (cs) 2001-11-14
AU5690599A (en) 2000-03-21
IL141586A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
AU751034B2 (en) Cyclic prosaposin-derived peptides and uses thereof
CA2168029C (en) Prosaposin and cytokine-derived peptides as therapeutic agents
CA2248139C (en) Methods of alleviating neuropathic pain using prosaposin-derived peptides
US5571787A (en) Prosaposin as a neurotrophic factor
AU751161B2 (en) Retro-inverso neurotrophic and analgesic peptides
US6849602B1 (en) Compositions for alleviating neuropathic pain with prosaposin receptor agonists
WO1998039357A1 (en) Method of alleviating neuropathic pain
WO1998042746A9 (en) Synthetic saposin c-derived neurotrophic peptides
WO1998042746A2 (en) Synthetic saposin c-derived neurotrophic peptides
EP1183266A1 (en) Retro-inverso peptides derived from leukemia inhibitory factor
MXPA01001966A (en) Cyclic prosaposin-derived peptides and uses thereof
US20020128193A1 (en) Retro-inverso prosaposin-derived peptides and use thereof
AU2002300005B2 (en) Method of alleviating neuropathic pain
AU4267297A (en) Method of alleviating neuropathic pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010321

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20011115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030612

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1039621

Country of ref document: HK